A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis.
Phase of Trial: Phase I/II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs AG 011 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors ActoGeniX
- 10 Jun 2017 Biomarkers information updated
- 15 Mar 2012 Actual end date changed from Sep 2009 to Nov 2009 as reported by European Clinical Trials Database.
- 15 Mar 2012 This trial is recruiting in Netherlands as reported by European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History